Treatment of Endometrial Hyperplasias with Gonadotropin-Releasing Hormone Agonists: Pathological, Clinical, Morphometric, and DNA-Cytometric Data
- 1 April 1997
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 65 (1), 102-114
- https://doi.org/10.1006/gyno.1997.4639
Abstract
No abstract availableKeywords
Funding Information
- Ministry of National Education and Religious Affairs
- Alexander von Humboldt-Stiftung
- Volkswagen Foundation
This publication has 25 references indexed in Scilit:
- Endometrial cancer: Stage at diagnosis and associated factors in black and white patientsAmerican Journal of Obstetrics and Gynecology, 1995
- Confirmation of the prognostic value of the ECPI-1 score (myometrial invasion, DNA-ploidy and mean shortest nuclear axis) in FIGO stage I endometrial cancer patients with long follow-upInternational Journal of Gynecologic Cancer, 1995
- Clinical Response of Abnormal Endometrial Growth to Hormonal TreatmentAnnals of the New York Academy of Sciences, 1994
- Tamoxifen and Endometrial CancerAnnals of the New York Academy of Sciences, 1994
- Minimal Deviation Adenocarcinoma of the Cervix: A Hypodiploid Tumor?International Journal of Gynecological Pathology, 1994
- DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Palliative Hormonal Treatment in Endometrial CarcinomaPublished by Springer Nature ,1991
- Endometrial CarcinomaInternational Journal of Gynecological Pathology, 1985
- DNA-Feulgen-cytophotometric analysis of single cells isolated from paraffin embedded tissuePathology - Research and Practice, 1984
- The prognostic significance of DNA measurements in endometrial carcinomaCytometry, 1984